Skip to Content
Merck
All Photos(1)

Documents

Y0000621

Terazosin hydrochloride dihydrate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride dihydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H25N5O4 · HCl · 2H2O
CAS Number:
70024-40-7
Molecular Weight:
459.92
MDL number:
MFCD00941408
UNSPSC Code:
41116107
PubChem Substance ID:
329831056
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

terazosin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O.O.Cl.COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4

InChI

1S/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2

InChI key

NZMOFYDMGFQZLS-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Terazosin hydrochloride dihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000622

Terazosin impurity A, European Pharmacopoeia (EP) Reference Standard

1643463

Terazosin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1643474

Terazosin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1643485

Terazosin Related Compound C, United States Pharmacopeia (USP) Reference Standard

Y0000665

Terazosin impurity E, European Pharmacopoeia (EP) Reference Standard

Y0000624

Terazosin impurity N, European Pharmacopoeia (EP) Reference Standard

1643452

Terazosin hydrochloride, United States Pharmacopeia (USP) Reference Standard

Y0000666

Terazosin for system suitability, CRS, European Pharmacopoeia (EP) Reference Standard

PHR1721

Terazosin Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

Y0002286

Terazosin for system suitability A, European Pharmacopoeia (EP) Reference Standard

PHR3137

Terazosin Related Compound A, certified reference material, pharmaceutical secondary standard

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H319

Hazard Classifications

Eye Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jun Sang Park et al.
Drug development and industrial pharmacy, 37(6), 664-672 (2011-04-01)
A novel three-layered tablet consisting of a water-soluble mid-layer and two barrier layers with swellable polymers was investigated to develop a preferable once-a-day formulation containing terazosin HCl as a hydrophilic model drug. When the tablet was exposed to a release
Britta J Veitenheimer et al.
American journal of physiology. Heart and circulatory physiology, 303(8), H1022-H1034 (2012-08-21)
Forty-eight hours of water deprivation (WD) in conscious rats results in a paradoxical increase in mean arterial pressure (MAP). Previous studies suggest this may be due to increased sympathetic nerve activity (SNA). However, this remains to be investigated in conscious
Karen M Alsene et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35(12), 2346-2356 (2010-08-06)
The psychotomimetic drug D-amphetamine (AMPH), disrupts prepulse inhibition (PPI) of the startle response, an operational measure of sensorimotor gating that is deficient in schizophrenia patients. Historically, this effect has been attributed to dopaminergic substrates; however, AMPH also increases norepinephrine (NE)
Irini P Chatziralli et al.
Ophthalmology, 118(4), 730-735 (2010-12-21)
To evaluate risk factors (hypertension, diabetes mellitus, and current tamsulosin, alfuzosin, terazosin, or doxazosin use) for intraoperative floppy iris syndrome (IFIS) in patients undergoing phacoemulsification cataract surgery. Systematic review and meta-analysis of the literature. Seventeen eligible studies (17 588 eyes)
M R Yadav et al.
Pharmaceutical biology, 50(4), 439-442 (2011-12-06)
The problem of hypertension has gained enormous proportions in the past decade. Multifactorial etiology and complex pathophysiology of the disease has rendered the treatment of the disease a hard task. Sympathetic nervous system and the renin-angiotensin-aldosterone system are primary contributors
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service